Endonovo Therapeutics, Inc.
ENDV · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -92.8% | 3.6% | 85.2% | – |
| Cost of Goods Sold | $1 | $1 | $0 | $0 |
| Gross Profit | -$1 | -$1 | $0 | $0 |
| % Margin | -6,125.6% | -366.9% | 92.6% | 79.5% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $1 | $2 | $3 | $2 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $1 | $1 |
| Operating Expenses | $1 | $2 | $3 | $2 |
| Operating Income | -$2 | -$3 | -$3 | -$2 |
| % Margin | -15,532.5% | -2,081.7% | -2,411.7% | -3,045.7% |
| Other Income/Exp. Net | -$1 | $10 | -$15 | -$1 |
| Pre-Tax Income | -$3 | $7 | -$18 | -$3 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$3 | $7 | -$18 | -$3 |
| % Margin | -27,853.2% | 4,937.6% | -13,649.2% | -4,247.2% |
| EPS | -0.005 | 0.025 | -0.13 | -0.052 |
| % Growth | -120.3% | 119.3% | -150.5% | – |
| EPS Diluted | -0.005 | 0.005 | -0.13 | -0.052 |
| Weighted Avg Shares Out | 544 | 276 | 139 | 60 |
| Weighted Avg Shares Out Dil | 544 | 1,351 | 139 | 60 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $1 | $1 | $1 | $1 |
| Depreciation & Amortization | $1 | $1 | $1 | $1 |
| EBITDA | -$1 | $9 | -$17 | -$2 |
| % Margin | -9,373.7% | 6,313.2% | -12,194.9% | -2,072.1% |